In Regard to Shee et al
Open Access
- 16 September 2022
- journal article
- letter
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 7 (5) , 100988
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 TrialAdvances in Radiation Oncology, 2022
- Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM TrialEuropean Urology Oncology, 2021
- Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trialThe Lancet Oncology, 2019
- Is it essential to use fiducial markers during cone-beam CT-based radiotherapy for prostate cancer patients?Japanese Journal of Radiology, 2016
- Image-Guided Radiotherapy (IGRT) for Prostate Cancer Comparing kV Imaging of Fiducial Markers With Cone Beam Computed Tomography (CBCT)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011